SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models
Open Access
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (4), e13076
- https://doi.org/10.15252/emmm.202013076
Abstract
Astrocytes and microglia are brain‐resident glia that can establish harmful inflammatory environments in disease contexts and thereby contribute to the progression of neuronal loss in neurodegenerative disorders. Correcting the diseased properties of glia is therefore an appealing strategy for treating brain diseases. Previous studies have shown that serum/ glucocorticoid related kinase 1 (SGK1) is upregulated in the brains of patients with various neurodegenerative disorders, suggesting its involvement in the pathogenesis of those diseases. In this study, we show that inhibiting glial SGK1 corrects the pro‐inflammatory properties of glia by suppressing the intracellular NFκB‐, NLRP3‐inflammasome‐, and CGAS‐STING‐mediated inflammatory pathways. Furthermore, SGK1 inhibition potentiated glial activity to scavenge glutamate toxicity and prevented glial cell senescence and mitochondrial damage, which have recently been reported as critical pathologic features of and therapeutic targets in Parkinson disease (PD) and Alzheimer disease (AD). Along with those anti‐inflammatory/neurotrophic functions, silencing and pharmacological inhibition of SGK1 protected midbrain dopamine neurons from degeneration and cured pathologic synuclein alpha (SNCA) aggregation and PD‐associated behavioral deficits in multiple in vitro and in vivo PD models. Collectively, these findings suggest that SGK1 inhibition could be a useful strategy for treating PD and other neurodegenerative disorders that share the common pathology of glia‐mediated neuroinflammation.Keywords
Funding Information
- National Research Foundation of Korea (2017R1A5A2015395, 2017M3A9B4062415, 2020M3A9D80399925)
This publication has 128 references indexed in Scilit:
- CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s DiseaseJournal of Neuroimmune Pharmacology, 2012
- Lamin B1 loss is a senescence-associated biomarkerMolecular Biology of the Cell, 2012
- Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?Molecular Neurobiology, 2012
- Mitochondria in NeurodegenerationAdvances in experimental medicine and biology, 2011
- Mitochondrial ROS fuel the inflammasomeCell Research, 2011
- Reactive Astrocytes As Therapeutic Targets for CNS DisordersNeurotherapeutics, 2010
- Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced DeathCell, 2009
- Role of Foxa1 in regulation of bcl2 expression during oxidative-stress-induced apoptosis in A549 type II pneumocytesCell Stress and Chaperones, 2009
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004